Back to top
more

DaVita (DVA)

(Delayed Data from NYSE)

$153.99 USD

153.99
475,303

+1.64 (1.08%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $153.98 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

Reasons to Add The Cooper Companies (COO) to Your Portfolio Now

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.

Inogen (INGN) Rises 127% Year to Date: What's Driving the Stock?

by Zacks Equity Research

Expanding product portfolio and high prospects for POC raise optimism for the Inogen (INGN) stock.

Glaukos (GKOS) Gains 63.5% YTD: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Alcon (ALC) Q2 Earnings Meet Estimates, Revenues Increase Y/Y

by Zacks Equity Research

Alcon (ALC) delivers impressive growth in Implantables and Contact Lenses in the second quarter of 2024.

Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now

by Zacks Equity Research

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why You Should Retain Nevro (NVRO) Stock for Now

by Zacks Equity Research

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

Why You Should Add HCA Healthcare (HCA) to Your Portfolio Now

by Zacks Equity Research

HCA Healthcare (HCA) remains well-poised for growth on growing emergency room visits, buyouts and solid cash flows.

GE HealthCare's (GEHC) Tie-Up to Boost Female Pelvic Healthcare

by Zacks Equity Research

GE HealthCare's (GEHC) latest collaboration is likely to equip clinicians with a toolset to deliver enhanced care to female patients and improve the patient experience.

Avantor (AVTR) Inks Deal to Optimize Portfolio, Reduce Debt

by Zacks Equity Research

Avantor's (AVTR) latest agreement is likely to enhance its focus on strategic growth opportunities and reduce its debt burden.

Vasundhara Sawalka headshot

4 Stocks Trading Near 52-Week High With More Upside Potential

by Vasundhara Sawalka

Investors target stocks that have lately been on a bull run. Stocks like PPC, THC, DVA and UHS are seeing price strength and have a high chance of carrying the momentum forward.

Masimo (MASI) Gets New Suitors for Its Consumer Business Sale

by Zacks Equity Research

Masimo (MASI) receives unsolicited requests from multiple entities for acquiring its consumer business. The company already received a non-binding term sheet confirmation from a third party in May.

Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now

by Zacks Equity Research

Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.

DaVita Inc. (DVA) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Accuray (ARAY) Q4 Earnings Lag Estimates, Gross Margin Shrinks

by Zacks Equity Research

Despite improving product sales, Accuray (ARAY) reports mixed fourth-quarter fiscal 2024 results.

Stereotaxis (STXS) Receives European Approval for GenesisX

by Zacks Equity Research

Stereotaxis (STXS) gains CE mark for GenesisX and plans to launch the system in 2025.

Labcorp (LH) Gains From New Collaborations Amid FX Issues

by Zacks Equity Research

Labcorp's (LH) Biopharma Laboratory Services business is benefiting from collaborations with leading pharmaceutical and biotechnology companies.

DaVita HealthCare (DVA) Is Up 0.56% in One Week: What You Should Know

by Zacks Equity Research

Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

Cardinal Health (CAH) Beats on Q4 Earnings, Ups '24 EPS View

by Zacks Equity Research

Cardinal Health's (CAH) fourth-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company raises its EPS guidance for fiscal 2024.

Reasons to Retain Veeva Systems (VEEV) in Your Portfolio Now

by Zacks Equity Research

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock. However, data security threats and escalating costs are concerning.

Quest Diagnostics (DGX) Gains From Innovation, Customer Wins

by Zacks Equity Research

A key driver in Brain Health growth is Quest Diagnostics' (DGX) Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF Tests for diagnosing and monitoring.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Neuronetics (STIM) Q2 Loss Wider Than Expected, Revenues Fall Y/Y

by Zacks Equity Research

Neuronetics' (STIM) second-quarter 2024 top-line results reflect lower revenues from NeuroStar Advanced Therapy System and Treatment sessions.

Haemonetics (HAE) Q1 Earnings Miss Estimates, Gross Margin Rises

by Zacks Equity Research

Haemonetics' (HAE) earnings lag estimates in the first quarter of fiscal 2025. However, the company remains confident about its strategy for sustained profitable growth.

AMN Healthcare (AMN) Q2 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

AMN Healthcare's (AMN) dismal results in the majority of its segments led to a soft overall second-quarter performance.